JP2009523422A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523422A5
JP2009523422A5 JP2008550435A JP2008550435A JP2009523422A5 JP 2009523422 A5 JP2009523422 A5 JP 2009523422A5 JP 2008550435 A JP2008550435 A JP 2008550435A JP 2008550435 A JP2008550435 A JP 2008550435A JP 2009523422 A5 JP2009523422 A5 JP 2009523422A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
immunogen
composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008550435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523422A (ja
JP5346588B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/000886 external-priority patent/WO2007087178A2/en
Publication of JP2009523422A publication Critical patent/JP2009523422A/ja
Publication of JP2009523422A5 publication Critical patent/JP2009523422A5/ja
Application granted granted Critical
Publication of JP5346588B2 publication Critical patent/JP5346588B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008550435A 2006-01-13 2007-01-12 コドン最適化したｉｌ−１５を用いるワクチンおよび免疫治療とその使用方法 Expired - Fee Related JP5346588B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75885606P 2006-01-13 2006-01-13
US60/758,856 2006-01-13
PCT/US2007/000886 WO2007087178A2 (en) 2006-01-13 2007-01-12 Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012272266A Division JP5801279B2 (ja) 2006-01-13 2012-12-13 コドン最適化したｉｌ−１５を用いるワクチンおよび免疫治療とその使用方法

Publications (3)

Publication Number Publication Date
JP2009523422A JP2009523422A (ja) 2009-06-25
JP2009523422A5 true JP2009523422A5 (enExample) 2011-02-10
JP5346588B2 JP5346588B2 (ja) 2013-11-20

Family

ID=38309748

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008550435A Expired - Fee Related JP5346588B2 (ja) 2006-01-13 2007-01-12 コドン最適化したｉｌ−１５を用いるワクチンおよび免疫治療とその使用方法
JP2012272266A Expired - Fee Related JP5801279B2 (ja) 2006-01-13 2012-12-13 コドン最適化したｉｌ−１５を用いるワクチンおよび免疫治療とその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012272266A Expired - Fee Related JP5801279B2 (ja) 2006-01-13 2012-12-13 コドン最適化したｉｌ−１５を用いるワクチンおよび免疫治療とその使用方法

Country Status (12)

Country Link
US (2) US8178660B2 (enExample)
EP (1) EP1976871B1 (enExample)
JP (2) JP5346588B2 (enExample)
KR (1) KR101421745B1 (enExample)
CN (1) CN101432300A (enExample)
AT (1) ATE533782T1 (enExample)
AU (1) AU2007208452B2 (enExample)
CA (1) CA2636867C (enExample)
DK (1) DK1976871T3 (enExample)
ES (1) ES2374458T3 (enExample)
MX (1) MX336112B (enExample)
WO (1) WO2007087178A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE533782T1 (de) * 2006-01-13 2011-12-15 Univ Pennsylvania Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
CN102333870B (zh) * 2011-02-16 2014-01-29 中国水产科学研究院黄海水产研究所 一种提高蛋白表达效率的方法及表达载体
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
CN106794263A (zh) * 2014-10-01 2017-05-31 宾夕法尼亚大学理事会 具有抗原和作为佐剂的白细胞介素‑21的疫苗
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
CA3059634A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
JP6437591B1 (ja) 2017-05-29 2018-12-12 旭化成株式会社 ポリエチレンパウダー及びその成形物
CN107868131A (zh) * 2017-10-13 2018-04-03 长春西诺生物科技有限公司 一种猪细小病毒病亚单位疫苗及其制备方法
WO2019118764A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting muc16 and uses thereof
MX2020006226A (es) 2017-12-13 2020-11-18 Inovio Pharmaceuticals Inc Vacunas contra el cancer dirigidas a mesotelina y usos de estas.
CA3083531A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting boris and uses thereof
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP4306641A4 (en) * 2021-02-05 2025-06-04 ST Pharm Co., Ltd. NEW NUCLEIC ACID MOLECULE
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
US20250243279A1 (en) 2023-10-17 2025-07-31 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2157994A (en) 1937-11-08 1939-05-09 Kelsey Hayes Wheel Co Brake mechanism
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
ZW17385A1 (en) 1984-11-06 1986-02-19 Hoffmann La Roche Tricyclic pyridine derivatives
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) * 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) * 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) * 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
AU625584B2 (en) * 1989-03-08 1992-07-16 Health Research Inc. Recombinant poxvirus host selection system
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69027313T2 (de) * 1989-03-31 1997-01-23 Univ Washington Impfstoffe enthaltende avirulente phop-type mikroorganismen
ES2070997T3 (es) * 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) * 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
IL108449A (en) 1993-01-26 2011-09-27 Weiner David B Assemblies and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (nl) * 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US7484671B2 (en) * 2003-07-31 2009-02-03 Smart Solar Limited Water feature
CA2567116A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
ATE533782T1 (de) * 2006-01-13 2011-12-15 Univ Pennsylvania Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Similar Documents

Publication Publication Date Title
JP2009523422A5 (enExample)
Martinez-Flores et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
JP2007516696A5 (enExample)
RU2014135053A (ru) Иммуногены для вакцинации против вич
JP2008529558A5 (enExample)
JP2008056679A5 (enExample)
JP2017530124A5 (enExample)
JP2017522907A5 (enExample)
JP2015509707A5 (enExample)
JP2017503482A5 (enExample)
RU2015135890A (ru) Композиция вакцины
Forner et al. Peptide-based vaccines: foot-and-mouth disease virus, a paradigm in animal health
JP2015501840A5 (enExample)
JP2016533332A5 (enExample)
JP2019506175A5 (enExample)
JP2014507146A5 (enExample)
RU2017127024A (ru) Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н
NZ735684A (en) Materials and methods for respiratory disease control in canines
JP2011517938A5 (enExample)
RU2015113826A (ru) Выделение вируса, родственного парвовирусу-2 собак, от енота
Guo et al. A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
JP2012517239A5 (enExample)
Beaumont et al. Prospects for prophylactic hepatitis C vaccines based on virus-like particles
CN102000330B (zh) 一种核酸疫苗佐剂及其构建方法
CN106421774B (zh) PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途